Nymox up on submitting marketing application for lead drug in Europe

Nymox Pharmaceutical

05/12/2022 16:53

** Shares of drug developer Nymox Pharmaceutical NYMX.O rise
as much as ~85% to near 4-month high of 53 cents 
    ** Co says  urn:newsml:reuters.com:*:nGNX7g0gmX it has submitted marketing
authorization request to Danish health authorities for lead drug
fexapotide triflutate as treatment for benign prostatic
hyperplasia (BPH) 
    ** BPH is condition that causes enlarged prostate glands and
urinary issues in older men
    ** Co says trademarked name for drug candidate in
application is Nymozarfex 
    ** About 2.7 mln shares change hands, more than 38x their
25-day average trading volume
    ** Including session moves, stock down ~68% YTD
 (Reporting by Akshita Toshniwal in Bengaluru)
 ((Akshita.Toshniwal@thomsonreuters.com))